about
Development of a Novel AAV Gene Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model of Rett SyndromeImproved MECP2 Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal Delivery.Insulin resistance in Chileans of European and indigenous descent: evidence for an ethnicity x environment interaction.Objective vs. self-reported physical activity and sedentary time: effects of measurement method on relationships with risk biomarkersFurther evidence for clustering of human GABAA receptor subunit genes: localization of the alpha 6-subunit gene (GABRA6) to distal chromosome 5q by linkage analysis.FTO genotype and adiposity in children: physical activity levels influence the effect of the risk genotype in adolescent males.Gait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficitsAssociation analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks.Mutation screening in Rett syndrome patients.Characterisation of CDKL5 Transcript Isoforms in Human and MouseAdverse metabolic and mental health outcomes associated with shiftwork in a population-based study of 277,168 workers in UK biobank.Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci.Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation.MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.Rett syndrome: from bed to bench.Sleep characteristics modify the association of genetic predisposition with obesity and anthropometric measurements in 119,679 UK Biobank participants.Reduced axonal diameter of peripheral nerve fibers in a mouse model of Rett syndrome.Evolutionary history of the ADRB2 gene in humans.Association analysis of ACE and ACTN3 in elite Caucasian and East Asian swimmers.The 'topping-up' effect: differences between low- and non-alcoholic lager on blood ethanol.Genome-wide analysis in UK Biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia.Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort.Tobacco exposure and sleep disturbance in 498 208 UK Biobank participants.Characterisation of Cdkl5 transcript isoforms in rat.Familial Ménière's disease: clinical and genetic aspects.Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p.Developmental changes in adiposity in toddlers and preschoolers in the GENESIS study and associations with the ACE I/D polymorphism.Synaptic plasticity deficits in an experimental model of rett syndrome: long-term potentiation saturation and its pharmacological reversal.The associations of ACE polymorphisms with physical, physiological and skill parameters in adolescentsp.R270X MECP2 mutation and mortality in Rett syndromeGenetics of self-reported risk-taking behaviour, trans-ethnic consistency and relevance to brain gene expressionGenomic mapping and evolution of human GABA A receptor subunit gene clustersDimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype–phenotype associations in Rett syndromeAnalysis of GABAA receptor subunit genes in multiplex pedigrees with manic depressionEffects of Interaction between Angiotensin I-Converting Enzyme Polymorphisms and Lifestyle on Adiposity in Adolescent GreeksGenetic variation in CADM2 as a link between psychological traits and obesitySchizophrenia and GABAA receptor subunit genesCandidate gene study of eight GABAA receptor subunits in panic disorderRegional workload induced changes in electrophysiology and immediate early gene expression in intact in situ porcine heart
P50
Q33652467-D74CC0B7-EC0D-498F-BFC7-FB9109032C40Q33655727-D052FEFA-CEB0-481D-9486-50719AB9EC15Q34023929-CD5A9AAF-1D8B-41A4-B5C1-DDAB9B5689DBQ34270702-45A7EDED-56CB-4433-AF15-563ACCD1B86FQ34329541-A5C63368-BBE7-4ECB-8408-67FE2E053FF5Q34410165-5CD3B921-638F-46A7-8158-1E9AE20EEBBCQ34506454-F20A17B7-DEE4-4F84-AC49-6049C8E80032Q34573167-0581AAE6-CFB5-4820-AA6E-4D07E2EFD56DQ35434415-11836DEF-5279-4E3E-958E-CF49432693A0Q36055559-6A5506E3-6D42-4FD5-9806-F591B11EDEA4Q36271869-27A10004-40C2-4BFE-A415-D2324F76D401Q36507871-7F918749-9BFE-427C-9E6F-5FC9BE023DDAQ36932866-3A9BF047-4384-4842-8FAD-28560F5C626AQ37004830-149D39C3-7E3F-44CE-8BB8-D9F4CC0E2685Q37932009-DDB70756-0863-43DA-84F1-4C2A5AA6015AQ37970799-E4CC5F80-FF05-4FF4-A6F0-D1AFDDA6D367Q38934000-E559068E-AC75-4D6B-BB8C-BF85D8606DD6Q40143992-1DB7EE69-707F-4DEB-9618-8F57CEBC8915Q42878578-4AC59154-0269-4B55-8272-6A81AA6A6E04Q43489734-7ACCFD18-00AC-4EDC-9DB1-5275683F46AEQ43530404-BA803247-82FA-4797-9C6D-7C658A9E0E77Q47349730-8CA881B5-A343-4E9D-ACA5-D63CE904AB24Q47549679-4DFC9191-8E56-4643-A570-8C771123A92EQ47672836-D2227BEA-D6B9-4ADF-91D2-F40043D57C26Q48399614-95005E9F-9517-4FF0-ACA9-390E944714B1Q50450774-BBCCF20D-ED2A-4F26-A28E-E8B6316C99FEQ50883448-899BE4DF-055F-4192-8767-AEA6A919D57CQ51989987-14508D09-D8CA-4BA8-ABFE-670EB352257BQ52607738-89F025FA-6F53-4B39-9B4E-B721E59EC1EAQ57243049-62246014-2F4F-4E09-A82C-E184F9AC1478Q57297413-5C95B70A-1F04-4762-AED2-D859310FD5DDQ57303386-0C881A66-5D78-40AC-841F-B58393499773Q57315619-5E0777A0-02FD-4872-A836-B855406EA431Q57421506-FBB7791F-7C64-4CB1-AC6C-7BC6004BCFC8Q58618068-801E17B0-EEA6-41DC-AF89-729859A299C4Q58806356-D77672C6-0F09-4EE3-B57A-7C91E3F6BA11Q64056803-54910690-6250-486F-AA6C-2270FB3E0B47Q71797590-EB8EB211-92D8-4C49-B747-DD99715A7F12Q73565153-A5EF639F-E2B7-45A5-8288-32D81732C399Q73955500-0A0A2CAD-B383-44C1-A777-6F69666EFFEC
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9788-2278
@en
name
Mark E. S. Bailey
@ast
Mark E. S. Bailey
@en
Mark E. S. Bailey
@es
Mark E. S. Bailey
@nl
type
label
Mark E. S. Bailey
@ast
Mark E. S. Bailey
@en
Mark E. S. Bailey
@es
Mark E. S. Bailey
@nl
prefLabel
Mark E. S. Bailey
@ast
Mark E. S. Bailey
@en
Mark E. S. Bailey
@es
Mark E. S. Bailey
@nl
P106
P1153
8896542700
P31
P496
0000-0002-9788-2278